Resource Logo
AIDS Weekly Plus

New Antimicrobial Agents and Chemotherapy Study Findings Recently Were Reported by Researchers at GlaxoSmithKline




 



2013 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Data detailed on Antimicrobial Agents and Chemotherapy have been presented. According to news reporting from Research Triangle Park, North Carolina, by NewsRx journalists, research stated, "HIV integrase inhibitors such as raltegravir and elvitegravir halt HIV progression, but treatment-emergent resistance and cross-resistance have been observed. The nonnucleoside reverse transcriptase inhibitor etravirine (ETR) may be used in combination with integrase inhibitors in patients with drug resistance."

The news correspondents obtained a quote from the research from GlaxoSmithKline, "This single-center, open-label, two-period, single-sequence crossover study evaluated the effects of ETR coadministration on the pharmacokinetic profile of S/GSK1265744, an investigational integrase inhibitor in phase 2 studies. Healthy subjects received 30 mg of S/GSK1265744 alone once daily for 10 days (period 1) and in combination with 200 mg of ETR twice daily for 14 days (period 2). Serial plasma samples for pharmacokinetic analyses were collected on day 10 during period 1 and on day 14 during period 2. All treatments were well tolerated. Etravirine had no effects on S/GSK1265744 geometric mean ratios of the area under the curve from time zero until the end of the dosing interval (1.01; 90% confidence interval [CI], 0.956 to 1.06), of the maximum observed plasma concentration (1.04; 90% CI, 0.987 to 1.09), or of the plasma concentration at the end of the dosing interval (0.999; 90% CI, 0.942 to 1.06). Etravirine pharmacokinetics (PK) parameters observed following coadministration with S/GSK1265744 were in the range of historical values reported for ETR alone in healthy subjects."

According to the news reporters, the research concluded: "These results indicate that 30 mg of S/GSK1265744 for 10 days as monotherapy followed by an additional 14 days in combination with ETR was well tolerated in healthy subjects and that no dose adjustment of S/GSK1265744 is required when it is coadministered with ETR."

For more information on this research see: Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744. Antimicrobial Agents and Chemotherapy, 2013;57(1):277-80. (American Society for Microbiology - www.asm.org; Antimicrobial Agents and Chemotherapy - aac.asm.org)

Our news journalists report that additional information may be obtained by contacting S.L. Ford, GlaxoSmithKline, Research Triangle Park, North Carolina, United States (see also Antimicrobial Agents and Chemotherapy).

Keywords for this news article include: Antimicrobial Agents and Chemotherapy, Pharmaceuticals, Drugs, Integrases, Recombinases, United States, North Carolina, Pharmacokinetics, Research Triangle Park, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC



 


Copyright © 2013 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in August 12, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.